On 1 July 2019, legislation came into effect that amends the EU Supplementary protection certificates (SPC) Regulation. This guide, prepared by the BIA’s IP Advisory Committee (IPAC), provides an overview for members concerning the changes.
The BIA has written to the Chancellor ahead of the 2019 Spending Round to highlight how the Government should maintain a competitive life sciences environment in the UK.
The BIA has responded to a call for views on draft legislation for the Supplementary Protection Certificate (SPC) manufacturing waiver in a 'no deal' outcome.
This is a briefing for BIA members on the new Government and key ministerial appointments for our sector.
The Alliance for Regenerative Medicine (ARM) and the BioIndustry Association (BIA) have published a report setting out the scope of the UK’s robust and growing Advanced Therapy Medicinal Products (ATMPs) sector which includes the development of potentially transformative cell and gene therapies.
The BioIndustry Association (BIA)’s ongoing engagement enables our members’ voices to be heard at the highest levels. This quarterly update gives an overview of key policy developments and the BIA’s continued engagement with policymakers, regulatory authorities and wider stakeholders on behalf of the UK life sciences sector, from April to July 2019.
The BIA has responded to the House of Commons Science and Technology Select Committee’s inquiry on commercial genomics.
In late June, the BIA sent this briefing to UK MEPs as they prepared to take up their seats in the European Parliament.
The BIA has submitted views to the Labour Party's Economy, Business and Trade Commission to inform its policy development.
The BIA has submitted views to the Labour Party's Health and Social Care Commission to inform its policy development.